Risk of Adverse Behavioral Effects with Pediatric Use of Antidepressants

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2006 Dec 21

PMID 17180618

Citations 23

Authors

Wayne K Goodman

Tanya K Murphy

Eric A Storch

Affiliations

Soon will be listed here.

Abstract

Objectives: This article reviews evidence that led the Food and Drug Administration to issue a "black box" warning about the risk of "suicidality" (suicidal thoughts and behavior) in children and adolescents during treatment with antidepressants.

Results: Re-analysis of data from randomized clinical trials of antidepressants in the pediatric population revealed a significantly greater overall (all drugs across all indications) risk ratio for drug 1.95 (95% Cl, 1.28-2.98) compared to placebo in this sample of approximately 4,000 subjects.

Discussion: The essential message of the "black box" is to remind prescribers and consumers about the importance of monitoring closely for adverse behavioral changes during the initiation of (or changes in) antidepressant therapy. Possible mechanisms that might account for this phenomenon, particularly the so-called activation syndrome, are discussed.

Conclusion: Empirical studies are needed to identify the precursors of suicidality and to predict which individuals are most susceptible to adverse behavioral side effects of antidepressants.

Citing Articles

Reactivity of Olanzapine and Tricyclic Antidepressants on the Protective Effects of Trolox on Lipid Peroxidation Evaluated Using Fluorescence Anisotropy, Electron Paramagnetic Resonance Spectrometry, and Thermal Analysis.

Horizumi Y, Tanada R, Kurosawa Y, Takatsuka M, Tsuchida T, Goto S ACS Chem Neurosci. 2025; 16(3):462-478.

PMID: 39818700 PMC: 11809279. DOI: 10.1021/acschemneuro.4c00702.

Psychotropic Medications Promote Time-Dependent Reduction of Suicidal Ideation in Mood Disorder: A Prospective Cohort Study.

Yang J, Park C, Rhee S, Kang D, Kim M, Lee H J Korean Med Sci. 2024; 39(31):e226.

PMID: 39137811 PMC: 11319105. DOI: 10.3346/jkms.2024.39.e226.

Multimodal Mental Health Digital Biomarker Analysis From Remote Interviews Using Facial, Vocal, Linguistic, and Cardiovascular Patterns.

Jiang Z, Seyedi S, Griner E, Abbasi A, Rad A, Kwon H IEEE J Biomed Health Inform. 2024; 28(3):1680-1691.

PMID: 38198249 PMC: 10986761. DOI: 10.1109/JBHI.2024.3352075.

Promoting OCD WEllness and resilience (POWER) study: Rationale, design, and methods.

Leuchter J, Kook M, Geller D, Hertz A, Garcia J, Trent E Psychiatry Res Commun. 2023; 3(2).

PMID: 37377947 PMC: 10299759. DOI: 10.1016/j.psycom.2023.100111.

The Change of Suicidal Ideation Over a 12-Week Naturalistic Treatment of Depression: Comparison Between Young People and Older Adults.

Jung Y, Jun T, Woo Y, Yim H, Kim J, Kim J Psychiatry Investig. 2023; 20(1):9-17.

PMID: 36721881 PMC: 9890046. DOI: 10.30773/pi.2022.0147.

References

Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L . Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature. 2002; 416(6879):396-400. DOI: 10.1038/416396a. View

Miller C, Fleischhacker W . Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000; 22(1):73-81. DOI: 10.2165/00002018-200022010-00006. View

Brosen K . Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004; 59(1):5-12. DOI: 10.2515/therapie:2004003. View

Wagner K . Diagnosis and treatment of bipolar disorder in children and adolescents. J Clin Psychiatry. 2004; 65 Suppl 15:30-4. View

Brown G, Ten Have T, Henriques G, Xie S, Hollander J, Beck A . Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA. 2005; 294(5):563-70. DOI: 10.1001/jama.294.5.563. View

Jick H, Kaye J, Jick S . Antidepressants and the risk of suicidal behaviors. JAMA. 2004; 292(3):338-43. DOI: 10.1001/jama.292.3.338. View

Khan A, Khan S, Leventhal R, Brown W . Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol. 2001; 4(2):113-8. DOI: 10.1017/S1461145701002322. View

Bedard A, Nichols S, Barbosa J, Schachar R, Logan G, Tannock R . The development of selective inhibitory control across the life span. Dev Neuropsychol. 2002; 21(1):93-111. DOI: 10.1207/S15326942DN2101_5. View

Post R . The impact of bipolar depression. J Clin Psychiatry. 2005; 66 Suppl 5:5-10. View

10.

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J . Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004; 292(7):807-20. DOI: 10.1001/jama.292.7.807. View

11.

Richmond T, Rosen D . The treatment of adolescent depression in the era of the black box warning. Curr Opin Pediatr. 2005; 17(4):466-72. DOI: 10.1097/01.mop.0000166347.53102.e7. View

12.

Akagi H, Kumar T . Lesson of the week: Akathisia: overlooked at a cost. BMJ. 2002; 324(7352):1506-7. PMC: 1123446. DOI: 10.1136/bmj.324.7352.1506. View

13.

Leonard H, Swedo S, Rapoport J, Koby E, Lenane M, Cheslow D . Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry. 1989; 46(12):1088-92. DOI: 10.1001/archpsyc.1989.01810120030006. View

14.

Delate T, Gelenberg A, Simmons V, Motheral B . Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv. 2004; 55(4):387-91. DOI: 10.1176/appi.ps.55.4.387. View

15.

Mitchell P, Malhi G . Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004; 6(6):530-9. DOI: 10.1111/j.1399-5618.2004.00137.x. View

16.

Brent D, Baugher M, Bridge J, Chen T, Chiappetta L . Age- and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry. 1999; 38(12):1497-505. DOI: 10.1097/00004583-199912000-00010. View

17.

Walkup J, Labellarte M . Complications of SSRI treatment. J Child Adolesc Psychopharmacol. 2001; 11(1):1-4. DOI: 10.1089/104454601750143320. View

18.

Olfson M, Marcus S, Shaffer D . Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Arch Gen Psychiatry. 2006; 63(8):865-72. DOI: 10.1001/archpsyc.63.8.865. View

19.

Youngstrom E, Findling R, Youngstrom J, Calabrese J . Toward an evidence-based assessment of pediatric bipolar disorder. J Clin Child Adolesc Psychol. 2005; 34(3):433-48. DOI: 10.1207/s15374424jccp3403_4. View

20.

Guile J . Sertraline-induced behavioral activation during the treatment of an adolescent with major depression. J Child Adolesc Psychopharmacol. 1996; 6(4):281-5. DOI: 10.1089/cap.1996.6.281. View